BYSI
BeyondSpring Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.73
+2.95%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.71
From 52W high−68.95%
Volume13195.00
Market cap$30.01M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.71
From 52W high
−68.95%
Volume
13195.00
Market cap
$30.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
44.6
MomentumView details →
1D Return
+2.95%
YTD Return
−55.83%
SummaryUpdated Jun 1, 2026
BeyondSpring Inc. (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in New York, New York. The company went public in March 2017 and focuses on developing innovative cancer therapies, particularly targeting chemotherapy-induced side effects and various forms of lung cancer. BeyondSpring's primary asset is Plinabulin, a novel drug that has completed Phase III clinical trials and represents the company's main pathway to potential commercialization and revenue generation.
Similar companies
Latest newsMore news →
BeyondSpring Inc. received a NASDAQ notice dated September 17, 2026 that it no longer complies with the $1.00 minimum bid price requirement under Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.2d agoBeyondSpring reported its second-quarter 2026 financial results and provided a corporate update.37d ago